. "Appendix D-1: The Prospects for Immunizing Against Dengue Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
TABLE D-1.1 Disease Burden: Dengue Fever
Under 5 Years
5–14 Years
15–59 Years
60 Years and Over
Morbidity Category
Description
Condition
Number of Cases
Duration
Number of Cases
Duration
Number of Cases
Duration
Number of Cases
Duration
A
Moderate localized pain and/or mild systemic reaction, or impairment requiring minor change in normal activities, and associated with some restriction of work activity
Dengue fever
7,500,000
4
14,500,000
4
500,000
4
B
Moderate pain and/or moderate impairment requiring moderate change in normal activities, e.g., housebound or in bed, and associated with temporary loss of ability to work
Dengue fever
4,000,000
5
7,000,000
5
4,000,000
5
C
Severe pain, severe short-term impairment, or hospitalization
Dengue hemorrhagic fever
20,000
6
40,000
6
D
Mild chronic disability (not requiring hospitalization, institutionalization, or other major limitation of normal activity, and resulting in minor limitation of ability to work)
n.a.
n.a.
n.a.
n.a.
E
Moderate to severe chronic disability (requiring hospitalization, special care, or other major limitation of normal activity, and seriously restricting ability to work)
